SPARCL1 and ovarian cancer: PrognoScan data suggested that the good prognosis was verified to be associated with elevated SPARCL1 in a breast cohort, a prostate cohort, and a lung cancer cohort and decreased SPARCL1 in a colorectal cohort and an ovarian cancer cohort.